Israel’s drugmaker Teva Pharmaceutical Industries has signed an agreement to acquire 51% equity share in US-based genomic-analysis firm Immuneering.
The deal’s terms have not been disclosed. Based in Cambridge, Massachusetts, US Immuneering provides data analysis services for pharmaceutical companies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The deal provides Teva exclusive rights to Immuneering’s cutting-edge analytics that can be used to develop treatments for diseases of the central nervous system (CNS).
Teva global R&D president and chief scientific officer Michael Hayden said: "Their ability to cut through, link and interpret enormous and disparate data-sets is outstanding.
"This capability is invaluable in capturing difficult-to-find signals, confirming them in follow-up experiments, and informing decision-making that de-risks and optimises development of therapeutic approaches."
Immuneering is involved in analysing data sets ranging from gene expression (microarray) data to single-nucleotide polymorphism (SNP) data, as well as protein concentration data to clinical meta data.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt also analyses next-generation sequencing (NGS) data, including RNA seq, and both exome and whole genome sequencing.
The company will use these data sets to capture difficult-to-find signals, generate biological hypotheses and design follow-up studies that can be used to develop medicines to treat patients with a wide range of serious diseases.
Immuneering CEO and co-founder Dr Ben Zeskind said: "Immuneering is pioneering new ways to use gene expression and genomic data to elucidate the biological mechanisms underlying both the development of disease, and the effectiveness of medicines."
Last month, Teva signed an agreement with Allergan to acquire its generic drug unit Allergan Generics for around $40.5bn.
